Chemicals and intermediates used in pharmaceutical manufacturing and drug development.
chemXplore tracks 135 projects in pharma, of which 36 are active.
19 new construction, 16 expansion, and 1 revamp / retrofit.
3 of the active projects carry no start-up date yet.
Owners and developers: Evonik Industries AG (4), Lilly (3), Merck (3), Novo Nordisk (3), Eli Lilly and Company (2), Genentech, Inc. (2)
Investors: Eli Lilly and Company (2), European Investment Bank (2), Evonik Industries AG (2), Takeda (2), AGC Group (1), Clariant AG (1)
Contractors, licensors, and offtakers are recorded on 13 of these 36 projects For subscribers
Targeting: Orforglipron (5), Retatrutide (2), Coagulation factor IX (1), Fumed Silica (1), Glucagon-like peptide-1 (1), Isobutene (1)
BLA for I‑DXd seeking accelerated approval in extensive‑stage SCLC withdrawn after FDA said Phase 2 data were insufficient; Phase 3 programmes continue.
Oral baricitinib showed substantial scalp, eyebrow and eyelash regrowth in a Phase 3 pediatric trial; 4 mg and 2 mg doses outperformed placebo at Week 36.
Single CARVYKTI infusion produced treatment-free, progression-free remissions at five years in half of early-line relapsed/refractory multiple myeloma patients.
Phase 4 STAR trial: guselkumab improved BASDAI at Week 24, reduced ASDAS‑CRP and MRI sacroiliac inflammation in biologic‑naïve axial PsA; safety profile consistent.
€15m first tranche of a €35m package to expand a Colombian plant to produce up to 250m doses annually, plus a €1.5m R&D grant for three vaccine candidates.
Tri-specific Wnt-pathway agonist showed non-inferior BCVA gains vs ranibizumab at week 52; higher rates of PDR, vitreous hemorrhage and discontinuations observed.
Passed a two-week unannounced FDA GMP inspection covering drug substance and drug product manufacturing, reinforcing U.S. commercial supply reliability.
FDA clears once‑weekly basal insulin that reduces injection frequency vs daily therapy; Phase 3 QWINT trials in >3,400 adults showed non‑inferior A1C vs glargine and degludec.
Modeling of MajesTEC‑3 trial data estimates a high cure fraction and nearly fourfold median OS benefit for teclistamab plus daratumumab FASPRO versus standard care in relapsed/refractory myeloma.
Interim analysis shows significant, clinically meaningful 24‑hour UPCR reduction at 37 weeks; blinded study continues to the eGFR endpoint at week 105.
By country, the most active first. active / all projects
The 8 with the most active projects, of 26 countries.
